基因表达谱与免疫组化双重确定细胞起源是弥漫大B细胞淋巴瘤最强生存预测因素
该回顾性多中心队列研究在359例统一治疗的瑞典和丹麦DLBCL患者中比较了Lymph2Cx GEP与Hans IHC算法判定COO的一致性及生存预测价值。GEP与IHC总体一致率为72%,GEP分型可显著区分OS和PFS,而IHC分型仅PFS有显著差异。IHC和GEP均判定为非GCB/ABC的患者预后最差,且在多变量分析中显著。
要点
- GEP与IHC判定COO总体一致率72%,IHC非GCB中58%被GEP归为ABC。
- GEP分型可显著预测OS和PFS,IHC分型仅PFS有显著差异。
- IHC与GEP双重判定的非GCB/ABC患者预后最差,多变量分析显著。
核心结论
- 同时使用IHC和GEP确定COO是识别DLBCL最差预后患者的最强预测方法。
- IHC和GEP均判定为非GCB/ABC的患者预后最差,且在多变量分析中显著。
研究设计与样本
- 回顾性多中心队列研究,纳入359例统一治疗的瑞典和丹麦DLBCL患者。
- 同时进行Lymph2Cx GEP和基于IHC的Hans算法判定COO。
主要发现
- GEP与IHC总体一致率为72%。
- IHC判定为GCB的病例中85%被GEP归为GCB,IHC判定为非GCB的病例中58%被GEP归为ABC。
- 按GEP分型,OS和PFS均有显著生存差异;按IHC分型,仅PFS有显著差异。
- IHC和GEP均判定为非GCB/ABC的患者预后最差,多变量分析显著。
- MYC和BCL2双表达在ABC病例中更常见,且与不良结局相关。
关键数值与推荐
- GEP与IHC总体一致率72%。
- IHC GCB中85%被GEP归为GCB;IHC非GCB中58%被GEP归为ABC。
临床怎么用
- 临床可联合IHC和GEP判定COO,以识别预后最差的DLBCL患者。
- 对IHC和GEP均判定为非GCB/ABC的患者应予以重点关注。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The tumor cells in diffuse large B-cell lymphomas (DLBCL) are considered to originate from germinal center derived B-cells (GCB) or activated B-cells (ABC). Gene expression profiling (GEP) is preferably used to determine the cell of origin (COO). However, GEP is not widely applied in clinical practice and consequently, several algorithms based on immunohistochemistry (IHC) have been developed. Our aim was to evaluate the concordance of COO assignment between the Lymph2Cx GEP assay and the IHC-based Hans algorithm, to decide which model is the best survival predictor. Both GEP and IHC were performed in 359 homogenously treated Swedish and Danish DLBCL patients, in a retrospective multicenter cohort. The overall concordance between GEP and IHC algorithm was 72%; GEP classified 85% of cases assigned as GCB by IHC, as GCB, while 58% classified as non-GCB by IHC, were categorized as ABC by GEP. There were significant survival differences (overall survival and progression-free survival) if cases were classified by GEP, whereas if cases were categorized by IHC only progression-free survival differed significantly. Importantly, patients assigned as non-GCB/ABC both by IHC and GEP had the worst prognosis, which was also significant in multivariate analyses. Double expression of MYC and BCL2 was more common in ABC cases and was associated with a dismal outcome. In conclusion, to determine COO both by IHC and GEP is the strongest outcome predictor to identify DLBCL patients with the worst outcome.
引用
- Abdulla M, Hollander P, Pandzic T, et al. Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma. Am J Hematol. 2019. PMID: 31659781. doi:10.1002/ajh.25666
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。